Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Complement C1 inhibitor protein - Takeda Inc

Drug Profile

Complement C1 inhibitor protein - Takeda Inc

Alternative Names: C1 Esterase Inhibitor (human); C1 INH-nf; C1-INH; Cetor; Cinryze; SHP-616; SHP616 Liquid; TAK-616

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanquin Blood Supply Foundation
  • Developer Prothya BioSolutions; Shire; Shire ViroPharma; Takeda; ViroPharma Incorporated
  • Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • No development reported Autoimmune haemolytic anaemia; Delayed graft function; Neuromyelitis optica
  • Discontinued Myocardial infarction; Paroxysmal nocturnal haemoglobinuria; Transplant rejection

Most Recent Events

  • 06 Jun 2019 Shire terminates a phase III trial in Transplant rejection in USA, Canada, Germany, Spain, France, Netherlands because following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility (IV) (NCT02547220)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 21 Jun 2018 Registered for Hereditary angioedema (In children, Prevention) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top